decisionhealth Newsletters, Coder Pink Sheets - 2005 Issue 3 (March)
Macugen gets supply code
Subscribe or sign in to view the full article.
Article Overview
This article discusses early billing and coverage guidance surrounding Macugen after FDA approval and CMS code assignment. It is aimed at ophthalmology practices, coders, and billers who need to understand the general Medicare payment context, claim-form documentation, and carrier policy updates affecting reimbursement for the drug and related services.
Why This Topic Matters
It helps readers track how newly approved drugs are handled in Medicare claims and where carrier policy differences may affect payment and documentation requirements.
What You Will Learn
- How CMS and carriers were handling billing for a newly approved ophthalmic drug.
- What kinds of Medicare coverage and documentation issues were being raised for treatment of age-related macular degeneration.
- How related injection services and associated office procedures were being treated in carrier guidance.
- How modifier use and diagnosis reporting were being discussed in connection with the claim process.
Who Should Read This
- Medical coders
- Billing staff
- Ophthalmology practices
- Revenue cycle professionals
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com